Effect of Tetrabenazine on Stroop Interference in HD

New York Medical College

Status and phase: Completed; Phase 4

Conditions: Huntington Disease

Treatments: Drug: Tetrabenazine withdrawal

Study type: Interventional

Funder types: Other

Identifiers

NCT01834911

L-10,830

Details and patient eligibility

About

Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Established diagnosis of Huntington disease by movement disorders expert
• Patients currently taking tetrabenazine.
• Patients should not have taken dopamine receptor blocking medication for at least three days

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 1 patient group

Tetrabenazine withdrawal

Experimental group

Description:

Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.

Treatment:

Drug: Tetrabenazine withdrawal